In the present study we have characterised the neutralising activity, IgG subclass profile, the potential for cross reactivity to endogenous interferon and complement activation of anti-drug antibodies to interferon beta in multiple sclerosis patients. The gene discussed is IFNB1; the disease is multiple sclerosis.